Search results
Showing 106 to 120 of 126 results for nivolumab
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued Reference number: GID-TA10970
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
This guidance has been updated and replaced by NICE technology appraisal guidance 780.
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued Reference number: GID-TA11421
Discontinued Reference number: GID-TA11289
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
In development Reference number: GID-TA11010 Expected publication date: TBC
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655.
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
This guidance has been updated and replaced by NICE technology appraisal guidance 713.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
In development Reference number: GID-TA10826 Expected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
In development Reference number: GID-TA11253 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 736.